{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:56:23Z","timestamp":1787014583871,"version":"build-2736575974"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T00:00:00Z","timestamp":1227484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Nonsedating H\n                    <jats:sub>1<\/jats:sub>\n                    \u2010antihistamines are recommended for the treatment of urticaria by the recent EAACI\/GA\n                    <jats:sup>2<\/jats:sup>\n                    LEN\/EDF guidelines. The aim of this study was to compare the efficacy, after 4\u2003weeks of treatment, with levocetirizine 5\u2003mg and desloratadine 5\u2003mg, both once daily in the morning, in symptomatic chronic idiopathic urticaria (CIU) patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    This multi\u2010center, randomized, double\u2010blind study involved 886 patients (438 on levocetirizine and 448 on desloratadine). The primary objective was to compare their efficacy on the mean pruritus severity score after 1\u2003week of treatment. Mean pruritus severity score over 4\u2003weeks and pruritus duration score, number and size of wheals, mean CIU composite score (sum of the scores for pruritus severity and numbers of wheals), quality of life, and the patient\u2019s and investigator\u2019s global satisfaction with treatment, were secondary efficacy measures.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Levocetirizine led to a significantly greater decrease in pruritus severity than desloratadine over the first treatment week; mean pruritus severity scores of 1.02 and 1.18 for levocetirizine and desloratadine, respectively (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    &lt;\n                    <jats:italic>\u2003<\/jats:italic>\n                    0.001). The result was similar for the entire 4\u2010week treatment period (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    =\n                    <jats:italic>\u2003<\/jats:italic>\n                    0.004). In addition, levocetirizine decreased pruritus duration and the mean CIU composite scores to a significantly greater extent than desloratadine during the first week (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    =\n                    <jats:italic>\u2003<\/jats:italic>\n                    0.002 and 0.005, respectively) and over the entire study (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    =\n                    <jats:italic>\u2003<\/jats:italic>\n                    0.009 and\n                    <jats:italic>P\u2003<\/jats:italic>\n                    &lt;\n                    <jats:italic>\u2003<\/jats:italic>\n                    0.05, respectively). Similarly, levocetirizine increased the patients\u2019 global satisfaction after one and 4\u2003weeks (\n                    <jats:italic>P\u2003<\/jats:italic>\n                    =\n                    <jats:italic>\u2003<\/jats:italic>\n                    0.012 and 0.021, respectively), compared with desloratadine. Safety and tolerability were similar in both groups.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    Levocetirizine 5\u2003mg was significantly more efficacious than desloratadine 5\u2003mg in the treatment of CIU symptoms.\n                  <\/jats:p>","DOI":"10.1111\/j.1398-9995.2008.01893.x","type":"journal-article","created":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T22:01:12Z","timestamp":1227564072000},"page":"596-604","source":"Crossref","is-referenced-by-count":66,"title":["Comparison of the efficacy of levocetirizine 5\u2003mg and desloratadine 5\u2003mg in chronic idiopathic urticaria patients"],"prefix":"10.1111","volume":"64","author":[{"given":"P. C.","family":"Potter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Guillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hauptmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Y.","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,12]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00130832-200310000-00008"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464220-00003"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1969.tb16041.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.116217"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04582.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2133.1997.d01-1168.x","article-title":"The impact of chronic urticaria on the quality oflife","volume":"136","author":"O\u2019Donnell BF","year":"1997","journal-title":"Br J Dermatol"},{"key":"e_1_2_7_8_2","first-page":"119","article-title":"Review of H1 antihistamines in the treatment of chronic idiopathic urticaria","volume":"76","author":"Monroe E","year":"2005","journal-title":"Cutis"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2005.00962.x"},{"issue":"1","key":"e_1_2_7_10_2","first-page":"3","article-title":"Comparative pharmacology of the H1 antihistamines","volume":"16","author":"Del Cuvillo A","year":"2006","journal-title":"J Investig Allergol Clin Immunol"},{"key":"e_1_2_7_11_2","first-page":"632","article-title":"Chronic urticaria: clinical aspects and focus on a new antihistamine, levocetirizine","volume":"3","author":"Kapp A","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02609.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.07049.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2001.00186.x"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.143"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200708010-00005"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2005.07.011"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61466-4"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2004.00254.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01436-5"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1529-8019.2000.00041.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-005-1368-3"},{"key":"e_1_2_7_24_2","article-title":"Inhibition of allergen\u2010induced wheal and flare reactions by levocetirizine and desloratadine","author":"Frossard N","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02662.x"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(97)70128-3"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-003-1193-5"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01897.x"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080657"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1472-9725.2002.00037.x"},{"key":"e_1_2_7_32_2","volume-title":"Xyzal 5\u2003mg film\u2010coated tablets, Xyzal 0.5\u2003mg\/ml oral solution, short product characteristics; 4.8 Undesirable effects. electronic Medicines Compendium"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04019.x"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07213.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2002.04758.x"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1398-9995.2008.01893.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1398-9995.2008.01893.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T20:38:17Z","timestamp":1697402297000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1398-9995.2008.01893.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1111\/j.1398-9995.2008.01893.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1398-9995.2008.01893.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1159161.619469","asserted-by":"object"}]},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,12]]}}}